Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Angiogenesis PET/CT in Neuroendocrine Tumors
NCT03271281Phase 2Completed
- Sponsor
- Rigshospitalet
- Start
- Dec 2017
- Primary completion
- Dec 2021
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of 68Ga-NODAGA-E(c[RGDyK])2 in neuroendocrine tumors (NETs), sponsored by Rigshospitalet. Primary endpoint: Angiogenesis PET/CT imaging of patients with neuroendocrine tumors at 1 hour. Started Dec 2017; status: completed.
02
Drugs
68Ga-NODAGA-E(c[RGDyK])2
03
Conditions
neuroendocrine tumors (NETs)
Beyond the preview
Go deeper on NCT03271281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03271281.